ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Monday, August 26th at 12:00 PM ET

Participants have the ability to submit questions live during the Q&A portion of the segment or pre-submit questions in advance of the segment by emailing cnsp@jtcir.com

HOUSTON, TX / ACCESSWIRE / August 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a Virtual Investor CEO Connect segment on Monday, August 26, 2024 at 12:00 PM ET.

As part of the virtual event, Mr. Climaco will provide a brief presentation, followed by an interactive Q&A session. Investors and interested parties will have the opportunity to submit questions live during the segment. Questions can also be pre-submitted leading up to the segment by emailing cnsp@jtcir.com. Mr. Climaco will answer as many questions as possible during the segment.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.



View the original press release on accesswire.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.46
-4.54 (-1.79%)
AAPL  270.04
+0.99 (0.37%)
AMD  250.05
-9.60 (-3.70%)
BAC  53.54
-0.02 (-0.04%)
GOOG  278.06
-6.06 (-2.13%)
META  627.32
-10.39 (-1.63%)
MSFT  514.33
-2.70 (-0.52%)
NVDA  198.69
-8.19 (-3.96%)
ORCL  248.17
-9.68 (-3.75%)
TSLA  444.26
-24.11 (-5.15%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.